Log ind
Bærbar scanner.jpg
Foto: DTU

New technology could revolutionize medtech firm’s business

Top picks in English:

Through the biggest project ever from Innovation Fund Denmark, researchers have developed an ultrasound scanning technology with the potential to transform the market. A medtech company involved in the project is now trying to figure out how to commercialize the invention.


BY LOUISE WENDT JENSEN
Offentliggjort 14.03.17 kl. 13:31

Log ind for at læse artikler

Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.

Prøv os gratis i 14 dage

Få fuld adgang til vores kvalitetsjournalistik med et gratis prøveabonnement.

Sign up for MedWatch newsletter
Mest læste Top picks in English

Here is what Danish drug companies pay their workers

Løn Top picks in English:

The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.

Danish hearing aid giants in global showdown

Top picks in English:

The world’s largest hearing device dealer, Amplifon, expresses concern over the entry into the retail market of manufacturers such as William Demant. GN Resound, on the other hand, receives praise and is expected to form even closer ties to its Italian collaborator.

Chemometec’s new growth engine could attract buyers

Top picks in English:

Chemometec is banking big on a new analysis device, scheduled for a broad launch during 2017. If the product lives up to the company’s own expectations, it could have wide-reaching consequences for the medtech company, one analyst believes.

Bavarian Nordic signs new commercial agreement

Top picks in English:

The Danish biotech company enters into a partnership with French counterpart which ensures Bavarian Nordic the rights to develop and commercialize new poxvirus-based vaccines.

Global venture boss keeps an eye on Danish biotech companies

Top picks in English:

Omega Funds receives 2200 applications from life science companies per year and 99.9 percent of these are turned down. But some Danish biotech companies have caught the attention of founder Otello Stampacchia and might be among the 0.1 lucky ones.

Novo among the 100 most valuable companies in the world

Top picks in English:

Novo Nordisk has made it onto the list of the world’s 100 most valuable companies for the first time, but the Danish company is still trailing the biggest players in the pharmaceutical industry.

Forsiden lige nu

Nyt opkøb i medicobranchen til trecifret mia-beløb

COLOURBOX14112799.jpg Medico & Rehab:

En amerikansk Coloplast-rival er på vej til at blive solgt for 24 mia. dollars – næsten 167 mia. kr. Handlen skal godkendes af myndighederne før den kan gå endeligt igennem.

Her vil Sanofi udfordre sine diabetesrivaler

Medicinal & Biotek:

Den franske medicinalkoncern Sanofi har kandidater på vej i to af de største nye lægemiddelklasser på diabetesområdet, og selskabets danske diabetesforskningschef mener, at man kan differentiere sig fra konkurrenter som blandt andre Novo Nordisk på vigtige parametre.

Markedet er ligeglad med AbbVies flotte hep c-resultater

Medicinal & Biotek:

AbbVie har netop fremlagt nye, stærke fase 3-resultater på deres lægemiddelkandidat mod hepatitis c, men hep c-markedet er så benhårdt, at analytikerne ikke giver meget for AbbVie chancer.

Laboratorieleverandør vokser på nordisk salg

Medico & Rehab:

Den danske laboratorieleverandør Ramcon glæder sig over fremgang i både bruttofortjeneste og årsresultat. Især har væksten været markant i Norden uden for Danmark.

MW-indeks: Investordarling vender kursen med flotte salgstal

Medicinal & Biotek:

En investordarling, som ellers har været prøvet på aktiekursen i de seneste uger, har med flotte nye salgstal vendt skuden, mens andre gode nyheder ikke finder nåde for investorernes blik.

Dansk biotekselskab leverer gyldent afkast i Sverige

Medicinal & Biotek:

Med en fantastisk kursudvikling siden sin børnotering i Sverige for små to år siden, går det rigtigt godt for danske Oncology Venture, som arbejder med at udvikle personlig kræftmedicin.

ANNONCE
ANNONCE


ANNONCE